Surrozen (SRZN) Accumulated Expenses (2020 - 2026)
Surrozen (SRZN) posted quarterly Accumulated Expenses of $6.7 million for Q1 2026, down 25.75% year-over-year from $9.1 million in Q1 2025, and down 14.7% quarter-over-quarter from $7.9 million in Q4 2025.
Surrozen (SRZN) Accumulated Expenses (2020 - 2026) Analysis & Trends
Surrozen's Accumulated Expenses history runs 7 years deep, the most recent figure standing at $6.7 million for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 25.75% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $6.7 million (down 25.75% YoY), while the FY2025 annual figure was $7.9 million, up 52.74% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $6.7 million, down from $7.9 million in the prior quarter.
- The five-year high for Accumulated Expenses was $9.1 million in Q1 2025, with the low at $3.5 million in Q1 2024.
- The 5-year median for Accumulated Expenses is $4.9 million (2022), against an average of $5.3 million.
- The sharpest annual moves came in 2022 and 2023: Accumulated Expenses jumped 399.4% in 2022, then sank 39.75% in 2023.
- Surrozen's Accumulated Expenses stood at $6.8 million in 2022, then tumbled by 39.75% to $4.1 million in 2023, then increased by 25.55% to $5.2 million in 2024, then jumped by 52.74% to $7.9 million in 2025, then dropped by 14.7% to $6.7 million in 2026.
- Business Quant data shows SRZN's Accumulated Expenses at $6.7 million in Q1 2026, $7.9 million in Q4 2025, and $4.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.95 Mn |
| Mar 31, 2026 | 6.75 Mn |
| Dec 31, 2025 | 7.91 Mn |
| Sep 30, 2025 | 4.75 Mn |
| Jun 30, 2025 | 4.19 Mn |
| Mar 31, 2025 | 9.09 Mn |
| Dec 31, 2024 | 5.18 Mn |
| Sep 30, 2024 | 4.32 Mn |
| Jun 30, 2024 | 3.64 Mn |
| Mar 31, 2024 | 3.49 Mn |
| Dec 31, 2023 | 4.13 Mn |
| Sep 30, 2023 | 3.95 Mn |
| Jun 30, 2023 | 3.90 Mn |
| Mar 31, 2023 | 5.32 Mn |
| Dec 31, 2022 | 6.85 Mn |
| Sep 30, 2022 | 6.13 Mn |
| Jun 30, 2022 | 6.01 Mn |
| Mar 31, 2022 | 4.93 Mn |
| Dec 31, 2021 | 8.66 Mn |
| Sep 30, 2021 | 8.50 Mn |